In February 2020, CENTOGENE N.V. Launched an Awareness Campaign in Mexico City, where More than 300 Participants have Gathered to Get Knowledge about Blau Syndrome, Symptoms its Diagnosis

 

According to a publication of 2019 entitled "Blau syndrome associated with nucleotide-binding oligomerization domain containing 2 mutations in a baby from Malaysia", this has been seen that due to rarity of the disease and lack of awareness, along with a limited number of genetic tests led to late diagnosis or even misdiagnosis of the disease.      

Access full Report @ https://www.databridgemarketresearch.com/reports/global-blau-syndrome-market

Global Blau syndrome market is expected to reach USD 12,856.08 thousand by 2027 from USD 5,566.40 thousand in 2019 growing with a CAGR of 11.9% in the forecast period of 2020 to 2027. The demand for Blau syndrome treatment has increased in both developed and developing countries, and the reason behind this is the high demand for disease-specific treatment worldwide. The Blau syndrome market is growing due to the high adoption of biological therapies, emergence of drugs used to treat symptoms associated with Blau syndrome, advancement in the healthcare industry and the availability of off-label drugs, among others.           

Blau Syndrome

Emergence of drugs used for the treatment of uveitis and nephritis, symptoms related to Blau syndrome across the world will drive the market's growth rate

Blau syndrome can affect various body parts. Most people with this syndrome also develop uveitis, which leads to inflammation in the middle layer of the eye, uvea. Moreover, patients having this syndrome also develop kidney disease that is nephritis, and nephrocalcinosis. As various symptoms are associated with Blau syndrome, different drugs, and treatment options have emerged for the treatment of Blau syndrome. This signifies that the emergence of drugs used for treating uveitis and nephritis, symptoms related to Blau syndrome, is expected to drive the market growth.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2020 to 2027

Base Year

2019

Historic Years

2018 (Customizable to 2013 - 2018)

Quantitative Units

Revenue in USD Thousand, Volumes in Units, Pricing in USD

Segments Covered

Type (Treatment and Diagnosis), Therapeutic Areas (Skin Rash, Inflammation), Route of Administration (Oral, Parenteral, Topical, Others), End User (Hospitals, Diagnostic Centers, Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada, Mexico in North America, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Brazil, Argentina, Rest of South America as a part of South America, UAE, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

Market Players Covered

Eli Lilly and Company (U.S.), AstraZeneca (U.K.), Novartis AG (Switzerland), Johnson & Johnson Private Limited (U.S.), Teva Pharmaceutical Industries Ltd.(Jerusalem), Merck & Co., Inc. (U.S.), Allergan (Ireland), Bausch Health Companies Inc. (Canada), Abbott (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Sanofi (France), Merck KGaA (Germany), Otsuka America Pharmaceutical, Inc. (U.S.), Akorn Operating Company LLC (U.S.), Allostera Pharma Inc. (Canada), I-Med Pharma Inc. (Canada), Santen Pharmaceuticals Co. Ltd., (Japan), AFT Pharmaceuticals (New Zealand), Novaliq GmbH (Germany) among others        

Data Points Covered in the Report

In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Segment Analysis:

Global Blau syndrome market is categorized into five notable segments on the basis of type, therapeutic areas, route of administration, end-user and distribution channel.

  • On the basis of type, the market is segmented into treatment and diagnosis.   In 2020, treatment segment is expected to dominate the market with 71.5% market share because Blau is a lifetime disorder and identified by many other disorders. So, patient can go only once for NOD2 test and treatment may continue for life.
  • On the basis of therapeutic areas, the market is segmented into skin rash and inflammation. In 2020, skin rash segment is expected to dominate the market with 54.7% market share because skin rash is the primary symptoms of Blau syndrome and 80-90% of affected children showed skin rash as a first symptom.
  • On the basis of route of administration, the market is segmented into oral, parenteral, topical and others. In 2020, oral segment is expected to dominate the market with 41.7% market share because in Blau disorder firstly oral therapy of corticosteroid and immunosuppressants are given to the affected child.
  • On the basis of end user, the market is segmented into hospitals, diagnostic centers, clinics, home healthcare and others. In 2020, hospitals segment is expected to dominate the market with 45.1% market share because in Blau syndrome affected individual may seek special guidance or help from the hospitals or patient may approach hospitals for the diagnosis of the disease.  

The hospitals segment will dominate the end user segment of the Blau syndrome market

The hospitals segment will emerge as the dominating segment end user segment. This is because of the growing number of hospitals in the market especially in the developing economies. Further, growth and expansion of research development services on a global scale will further bolster the growth of this segment.

  • On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, direct tender and others. In 2020, hospital pharmacy segment is expected to dominate the global market with 50.2% market share as patient first go the hospitals for treatment, so hospital pharmacy has various kind of medicines according to the patient need and fast contact point for patients for treatments and procedures.

The hospital pharmacy segment will dominate the distribution channel segment of the Blau syndrome market

The hospital pharmacy segment will emerge as the dominating segment under distribution channel with approximately 50.00% market share. This is because of the growing number of infrastructural development activities in the market, especially in developing economies. Further, growth and expansion of the healthcare industry all around the globe will further bolster the growth of this segment.

Major Players

Data Bridge Market Research recognizes the following companies as the market players in Blau syndrome market: Eli Lilly and Company (U.S.), AstraZeneca (U.K.), Novartis AG (Switzerland), Johnson & Johnson Private Limited (U.S.), Teva Pharmaceutical Industries Ltd.(Jerusalem), Merck & Co., Inc. (U.S.), Allergan (Ireland), Bausch Health Companies Inc. (Canada), Abbott (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Sanofi (France), Merck KGaA (Germany), Otsuka America Pharmaceutical, Inc. (U.S.).

Blau Syndrome

Market Development

  • In February 2020, Prognos Health launched the Rare Disease Institute with a focus on improving treatment and diagnosis of rare disease. The company stated as there are various types of rare disease exists in the market and more than thirty million people in the U.S. reported to get misdiagnosed, this launch will help the company, health care professional and patients to achieve a proper diagnosis and treatment for rare disease involving Blau syndrome, among others.
  • In September 2019, Blueprint Genetics (Clinical genetics firm) and Archimedlife Medical Laboratory (rare disease Diagnostics Company) launched rare disease testing in North America. This testing will provide next generation sequencing based testing for diagnosis of rare disease symptoms involving Blau syndrome, among others
  • In February 2020, CENTOGENE N.V. launched an awareness campaign Hotel Marriot Reforma in Mexico City, where more than 300 participants gathered knowledge about rare disease, symptoms, and its diagnosis, among others. As Blau syndrome is one of the rare diseases and the company is engaged in providing Next Generation Sequencing (NGS) panels for the categorization of symptoms associated with Blau syndrome, this campaign launch helped the company to enhance its diagnosis platform
  • In November 2019, Sandoz signed an acquisition agreement in order to acquire the Japanese business of Aspen Global Incorporated (AGI). This acquisition will help the company to expand its brand portfolio and pipeline of hospital generics (such as generic drugs for Blau syndrome treatment like Infliximab).

Regional Analysis

Geographically, the countries covered in the Blau syndrome market report are U.S., Canada, Mexico in North America, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Brazil, Argentina, Rest of South America as a part of South America, UAE, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

As per Data Bridge Market Research analysis:

North America is the dominant region in Blau syndrome market during the forecast period 2020 - 2027

North America is expected to dominate the market due to the region's high healthcare and research & development expenditure.

Asia-Pacific is estimated to be the fastest-growing region in Blau syndrome market the forecast period 2020 - 2027

Asia-Pacific is expected to grow with the highest CAGR in the forecasted periods due to increasing healthcare expenditure by the hospital in medical devices in the region and increasing prevalence of autoimmune inflammatory diseases.  

COVID-19 Impact

The COVID-19 epidemic has had a disastrous effect on the population and economy of the entire world. Healthcare systems are under a lot of stress as a result of the pandemic. In order to reduce the risk of transmission and save money for COVID-19 patients, healthcare institutions and providers have been directed to halt performing elective surgical operations and medical evaluations during this time. However, pharmaceutical and biotechnological industries are expected to grow at a staggering rate, which will positively impact the world.

For more detailed information about the Blau syndrome on market report, click here – https://www.databridgemarketresearch.com/reports/global-blau-syndrome-market